相关实验视频
Updated: May 16, 2025
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
18.3K
在精神分裂症患者中,临床医生遵守指南推的治疗和记忆功能之间的关系
Yasushi Kawamata1, Kazutaka Ohi2, Satsuki Ito3
1Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Japan.
Journal of psychiatric research
|April 4, 2025
概括
精神科医生遵守精神分裂症治疗指南会对患者的记忆和注意力产生积极影响. 改善指南教育可能有助于减轻精神分裂症患者的认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 认知科学 认知科学
背景情况:
- 精神分裂症显著损害记忆功能,构成治疗挑战.
- 非推的药物,如二类药物和抗胆固醇药物,可能会恶化认知功能.
- 精神科医生遵守精神分裂症患者记忆指南的影响尚不清楚.
研究的目的:
- 研究精神病医生遵守精神分裂症治疗指南与患者的记忆功能之间的关联.
- 确定粘附是否与特定的认知领域相关,如语言记忆,注意力和回忆.
主要方法:
- 使用个人适应性评分 (IFS) 来评估精神科医生对每个患者的指导方针的遵守.
- 在351名精神分裂症患者中使用韦克斯勒记忆量表 (Wechsler Memory Scale-Revised) 评估记忆功能 (40名治疗耐药,311名非治疗耐药).
主要成果:
- 在所有患者中,精神病学执法与口头记忆,注意力/集中力和延迟回忆有积极的相关性.
- 还观察到与视觉记忆的正相关性.
- 在不耐治疗的精神分裂症患者中,坚持治疗与延迟回忆,口头记忆和注意力/集中力的改善有关.
- 在治疗耐药的精神分裂症患者中,精神病学坚持和记忆功能之间没有发现显著的关联.
结论:
- 加强精神病学家对治疗指南的教育可能会改善精神分裂症的认知障碍.
- 遵守指南是增强精神分裂症认知功能的潜在可修改因素.
相关概念视频
01:28Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
01:26Psychosis: Goals of Pharmacotherapy
98
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
98
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
01:29Psychological and Sociocultural Causes of Schizophrenia
39
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
39
01:23Role of Neurotransmitters in Memory
334
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
334
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86